- Home
- TARS vs APGE Comparison
TARS vs APGE Comparison
Compare TARS & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARS
- APGE
- Stock Information
- Founded
- TARS 2016
- APGE 2022
- Country
- TARS United States
- APGE United States
- Employees
- TARS N/A
- APGE N/A
- Industry
- TARS Medicinal Chemicals and Botanical Products
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TARS Health Care
- APGE Health Care
- Exchange
- TARS Nasdaq
- APGE Nasdaq
- Market Cap
- TARS 1.8B
- APGE 2.1B
- IPO Year
- TARS 2020
- APGE 2023
- Fundamental
- Price
- TARS $40.65
- APGE $41.96
- Analyst Decision
- TARS Strong Buy
- APGE Strong Buy
- Analyst Count
- TARS 7
- APGE 4
- Target Price
- TARS $67.14
- APGE $91.33
- AVG Volume (30 Days)
- TARS 552.3K
- APGE 785.6K
- Earning Date
- TARS 08-07-2025
- APGE 08-11-2025
- Dividend Yield
- TARS N/A
- APGE N/A
- EPS Growth
- TARS N/A
- APGE N/A
- EPS
- TARS N/A
- APGE N/A
- Revenue
- TARS $233,674,000.00
- APGE N/A
- Revenue This Year
- TARS $122.94
- APGE N/A
- Revenue Next Year
- TARS $44.14
- APGE $743.14
- P/E Ratio
- TARS N/A
- APGE N/A
- Revenue Growth
- TARS 449.03
- APGE N/A
- 52 Week Low
- TARS $20.08
- APGE $26.20
- 52 Week High
- TARS $57.28
- APGE $63.50
- Technical
- Relative Strength Index (RSI)
- TARS 40.26
- APGE 56.93
- Support Level
- TARS $39.25
- APGE $40.67
- Resistance Level
- TARS $42.01
- APGE $44.65
- Average True Range (ATR)
- TARS 1.93
- APGE 2.48
- MACD
- TARS -0.05
- APGE 0.18
- Stochastic Oscillator
- TARS 22.95
- APGE 70.41
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.